Passage Bio, Inc.
A clinical-stage gene therapy company developing one-time treatments for rare brain and nervous-system diseases. Founded in 2019 as a spinout of the University of Pennsylvania's Gene Therapy Program, it builds on the work of gene-therapy pioneer James Wilson. Its name comes from "passaging" — the lab process of growing and purifying the harmless viruses that carry therapeutic genes into cells. Its lead programs target rare disorders such as GM1 gangliosidosis and Krabbe disease.
Bought 2.46M · Sold 1.97M
Bought 225.0K
Bought 550.0K
Bought 225.0K
Bought 550.0K
Bought 552.8K
Bought 1.04M
Bought 6.5K
Granted 72.0K · Bought 2.5K · Sold 17.6K
Granted 55.0K · Sold 17.5K
Granted 50.0K · Bought 2.0K · Sold 15.8K
Granted 25.0K · Bought 5.5K · Sold 7.8K
Granted 37.5K · Sold 13.5K
Bought 18.9K
Bought 13.1K
Granted 10.0K · Sold 4.1K
Bought 2.6K
Granted 47.0K · Sold 17.4K
Bought 5.0K
Granted 5.0K · Sold 1.7K
Granted 10.0K · Sold 10.0K
Bought 5.0K · Sold 5.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Orbimed Advisors LLC +1 co-filer10% owner · 40 transactions | — | 12.72Mas of Jun 2025 | — | 2.46M | 1.97M |
| Woiwode Thomas +6 co-filers10% owner, Director, 10% owner · 4 transactions | — | 4.73Mas of Mar 2020 | — | 225.0K | — |
| Topper James N +3 co-filers10% owner · 4 transactions | — | 4.46Mas of Mar 2020 | — | 550.0K | — |
| Woiwode ThomasDirector, 10% owner · 4 transactions | — | 3.69Mas of Mar 2020 | — | 225.0K | — |
| Heron Patrick JDirector, 10% owner · 4 transactions | — | 2.98Mas of Mar 2020 | — | 550.0K | — |
| Ratcliffe LiamDirector · 3 transactions | — | 2.07Mas of Mar 2020 | — | 552.8K | — |
| Lynx1 Capital Management LP +1 co-filer10% owner · 11 transactions | — | 673.8K | — | 1.04M | — |
| Yamada TadatakaDirector · 1 transaction | — | 656.1Kas of Mar 2020 | — | 6.5K | — |
| Quigley Jill M.Chief Operating Officer · 5 transactions | — | 372.4Kas of Dec 2021 | 72.0K | 2.5K | 17.6K |
| Forman Mark SCHIEF MEDICAL OFFICER · 4 transactions | — | 48.6Kas of Feb 2024 | 55.0K | — | 17.5K |
| Cale Edgar B.GC & Corporate Secretary · 3 transactions | — | 46.0Kas of Jan 2024 | 50.0K | 2.0K | 15.8K |
| Fotopoulos AlexandrosChief Technical Officer · 5 transactions | — | 28.7Kas of Jun 2023 | 25.0K | 5.5K | 7.8K |
| King SimonaChief Financial Officer · 4 transactions | — | 24.0Kas of Jul 2023 | 37.5K | — | 13.5K |
| Countouriotis AthenaDirector · 2 transactions | — | 18.9Kas of Mar 2020 | — | 18.9K | — |
| Goldsmith Bruce ACEO and President, Director · 3 transactions | — | 16.0Kas of Mar 2022 | — | 13.1K | — |
| Chou WilliamPRESIDENT AND CEO, Director · 2 transactions | — | 6.5K | 10.0K | — | 4.1K |
| Morris Richard StevenChief Financial Officer · 2 transactions | — | 5.5Kas of May 2021 | — | 2.6K | — |
| Borthwick KathleenCFO · 8 transactions | — | 5.4K | 47.0K | — | 17.4K |
| Islam SaqibDirector · 1 transaction | — | 5.0Kas of Mar 2020 | — | 5.0K | — |
| Toernsen Monika MariaChief Commercial Officer · 2 transactions | — | 3.3Kas of Sep 2022 | 5.0K | — | 1.7K |
| Romano GaryChief Medical Officer · 3 transactions | — | 0as of Mar 2021 | 10.0K | — | 10.0K |
| Kapadia SandipDirector · 2 transactions | — | 0as of Dec 2022 | — | 5.0K | 5.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +3.59M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.